BusinessWire Wugen Presents Data on WU-NK-101 in Combination with Cetuximab in Preclinical Models of Advanced… Business Wire News Jan 21, 2023 -- WU-NK-101 overcomes limitations encountered with other adoptive cell therapies in solid tumors -- -- WU-NK-101 exhibited robust trafficking, intra-tumor infiltration, and persistence in xenograft tumor models which were further…